Loading clinical trials...
Loading clinical trials...
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Conditions
Interventions
Atezolizumab
Bevacizumab
+1 more
Locations
22
United States
Los Angeles County-USC Medical Center
Los Angeles, California, United States
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States
Keck Medical Center of USC Pasadena
Pasadena, California, United States
University of Colorado Hospital
Aurora, Colorado, United States
Moffitt Cancer Center
Tampa, Florida, United States
Emory University Hospital Midtown
Atlanta, Georgia, United States
Start Date
March 10, 2017
Primary Completion Date
October 1, 2020
Completion Date
January 13, 2021
Last Updated
February 21, 2023
NCT05639972
NCT06654011
NCT02466971
NCT04622670
NCT04580771
NCT02257528
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions